Insys Therapeutics Submits NDA For New Oral Formulation Of Dronabinol

(RTTNews) - Insys Therapeutics, Inc. (INSY), a specialty pharmaceutical company developing and commercializing innovative drugs and novel drug delivery systems, Tuesday said it has submitted a New Drug Application to the U.S. Food and Drug Administration for its proprietary Dronabinol Oral Solution for anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Dronabinol Oral Solution is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a synthetic version of tetrahydrocannabinol.

The firm also announced second-quarter financial results. Net income increased to $9.5 million, or $0.26 per share, from $4.5 million, or $0.17 per diluted share, for the second quarter of 2013.

Two analysts polled by Thomson Reuters expected earnings of $0.30 per share for the quarter. Analysts' estimates typically exclude special items.

Total net revenue increased to $55.7 million from $18.8 million for the second quarter of 2013. Analysts expected revenues of $52.77 million.